deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT03647488

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Phase II Multicenter Randomized Two-arm Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Pretreated Adult Patients With EGFR Wild-type ALK Rearrangement Negative Advanced/Metastatic Non-small Cell Lung Cancer

Sponsor: Novartis Pharmaceuticals

Conditions Carcinoma, Non-Small-Cell Lung
Interventions Capmatinib Docetaxel Spartalizumab
Updated 18 times since 2018 Last updated: Jan 21, 2022 Started: Dec 26, 2018 Primary completion: Sep 7, 2020 Completion: Sep 7, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Carcinoma, Non-Small-Cell Lung, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 18 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2018 – ~Feb 2019 · 5 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Feb 2020 · 6 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Nov 2021 · 6 months · monthly snapshot~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~Jul 2024 · 29 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Feb 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Nov 2021 — Feb 2022 [monthly]

    Completed PHASE2

▶ Show 13 earlier versions

  1. May 2021 — Nov 2021 [monthly]

    Completed PHASE2

  2. Jan 2021 — May 2021 [monthly]

    Completed PHASE2

  3. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Aug 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  8. Aug 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

  9. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  10. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2

  11. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  12. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Sep 2018 — Feb 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations